ABSTRACT
Background Glutamatergic neuron-glioma synaptogenesis and peritumoral hyperexcitability promote glioma growth in a positive feedback loop. The objective of this study was to evaluate the feasibility and estimated effect sizes of the AMPA-R antagonist, perampanel, on intraoperative electrophysiologic hyperexcitability and clinical outcomes.
Methods An open-label trial was performed comparing perampanel to standard of care (SOC) in patients undergoing resection of newly-diagnosed radiologic high-grade glioma. Perampanel was administered as a pre-operative loading dose followed by maintenance therapy until progressive disease or up to 12-months. SOC treatment involved levetiracetam for 7-days or as clinically indicated. The primary outcome of hyperexcitability was defined by intra-operative electrocorticography high frequency oscillation (HFO) rates. Seizure-freedom and overall survival (OS) were estimated by the Kaplan-Meier method. Tissue concentrations of perampanel, levetiracetam, and metabolites were measured by mass spectrometry.
Results HFO rates were similar between perampanel-treated and SOC cohorts. The trial was terminated early after interim analysis for futility, and outcomes assessed in 11 patients (7 perampanel-treated, 4 SOC). Over a median 281 days of post-enrollment follow-up, 27% of patients had seizures, including 14% treated with perampanel and 50% treated with SOC. OS in perampanel-treated patients was similar to a glioblastoma reference cohort (p=0.81). Glutamate concentrations in surface biopsies were positively correlated with HFO rates in adjacent electrode contacts and were not significantly associated with treatment assignment or drug concentrations.
Conclusions A peri-operative loading regimen of perampanel was safe and well-tolerated, with similar peritumoral hyperexcitability as in levetiracetam-treated patients. Maintenance anti-glutamatergic therapy was not observed to impact survival outcomes.
Competing Interest Statement
S.T. received non-monetary research support for this study from Eisai (FYC-IIS-M001-1100) in the form of perampanel study drug, and has served in consulting roles for Blackrock Neurotech. K.L.L. is the founder and equity holder of Travera, a consultant for BMS, Integragen, Blaze Bioscience, and has received research support from BMS and Lilly. E.A.C. is an advisor to Bionaut Labs, Genenta Inc, Insightec Inc, Seneca Therapeutics, Theriva Biologics, has equity options in Bionaut Laboratories, Immunomic Therapeutics, Seneca Therapeutics, and Ternalys Therapeutics, is co-founder and on Board of Directors of Ternalys Therapeutics, has received research support from Advantagene, NewLink Genetics and Amgen, and has patents related to oncolytic viruses under the possession of Brigham and Womens Hospital licensed to Candel Therapeutics, Inc. T.R.S. has equity options in Phebe Health. P.Y.W. has served in consulting or advisory roles to AstraZeneca, VBI Vaccines, Bayer, Prelude Therapeutics, Mundipharma, Black Diamond Therapeutics, Day One Biopharmaceuticals, Sapience Therapeutics, Celularity, Novartis, Merck, Chimerix, Servier, Insightec, Novocure, Sagimet Biosciences, Boehringer Ingelheim, Servier, Genenta Science, Prelude Therapeutics, GlaxoSmithKline, Anheart Therapeutics, Kintara Therapeutics, Mundipharma, Novocure, SymBio Pharmaceuticals, Tango Therapeutics, Telix Pharmaceuticals, and received research funding from AstraZeneca, Merck, Novartis, Lilly, MediciNova, Vascular Biogenics, VBI Vaccines, Bayer, Nuvation Bio, Chimerix, Karyopharm Therapeutics, Servier, Black Damond, Erasca, Inc, Quadriga Biosciences. N.Y.R.A. is a key opinion leader for Bruker Daltonics and receives research support from EMD Serono and Thermo Finnigan. J.W.L. is co-founder of Sotyera, a consultant for SK Biopharmaceuticals, and performs contract work for Bioserenity and Teladoc. The remaining authors declare no competing interests.
Clinical Trial
NCT04497142
Funding Statement
National Cancer Institute (P50CA165962 to S.T., K.L.L., N.Y.R.A); National Cancer Institute (U54CA210180 supporting N.Y.R.A); National Institute of Biomedical Imaging and Bioengineering (P41EB015898 supporting N.Y.R.A and A.J.G.); Dana-Farber Cancer Institute PLGA Fund (supporting N.Y.R.A); Massachusetts Life Sciences Center (supporting N.Y.R.A)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Dana-Farber Cancer Institute gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 3 revised for color issue on file conversion
DATA AVAILABILITY
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
